CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire

08/05

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45^th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025.

Presentation Details
Format: Fireside Chat
Date: Tuesday, August 12, 2025
Time: 2:00 PM ET
Webcast Link: https://wsw.com/webcast/canaccord108/crvo/2537558

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557453391"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557453391\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557453391?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557453391","market":"us","top_or_hot":-1,"title":"CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference","media":"GlobeNewswire","content":"<html><body><p>BOSTON, Aug.  05, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45<sup>th</sup> Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025.</p> <p><strong>Presentation Details</strong><br/>Format: Fireside Chat<br/>Date: Tuesday, August 12, 2025<br/>Time: 2:00 PM ET<br/>Webcast Link: <u>https://wsw.com/webcast/canaccord108/crvo/2537558</u></p> <p>The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.</p> <p><strong>About CervoMed</strong><br/>CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.</p> <p><strong>Investor Contact: </strong><br/>PJ Kelleher<br/>LifeSci Advisors<br/><a href=\"https://laohu8.com/S/ISBC\">Investors</a>@cervomed.com<br/>617-430-7579</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MmFhYWU0NzktMmZiNy00NjcwLTg0ZDUtZGM1NzgwOTRlNjk3LTUwMDEyMTE2MC0yMDI1LTA4LTA1LWVu/tiny/CervoMed-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2025-08-05 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>BOSTON, Aug.  05, 2025  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45<sup>th</sup> Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025.</p> <p><strong>Presentation Details</strong><br/>Format: Fireside Chat<br/>Date: Tuesday, August 12, 2025<br/>Time: 2:00 PM ET<br/>Webcast Link: <u>https://wsw.com/webcast/canaccord108/crvo/2537558</u></p> <p>The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.</p> <p><strong>About CervoMed</strong><br/>CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.</p> <p><strong>Investor Contact: </strong><br/>PJ Kelleher<br/>LifeSci Advisors<br/><a href=\"https://laohu8.com/S/ISBC\">Investors</a>@cervomed.com<br/>617-430-7579</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MmFhYWU0NzktMmZiNy00NjcwLTg0ZDUtZGM1NzgwOTRlNjk3LTUwMDEyMTE2MC0yMDI1LTA4LTA1LWVu/tiny/CervoMed-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVO","symbol_name":"CervoMed","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/08/05/3127267/0/en/CervoMed-to-Participate-in-the-Canaccord-Genuity-45th-Annual-Growth-Conference.html","article_id":"2557453391","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557453391","pubTimestamp":1754395200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"BOSTON, Aug.  05, 2025  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVO":"CervoMed","BK4139":"生物科技"},"translate_title":"CervoMed将参加Canaccord Genuity第45届年度增长会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVO":1},"content_text":"BOSTON, Aug.  05, 2025  (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, August 12, 2025Time: 2:00 PM ETWebcast Link: https://wsw.com/webcast/canaccord108/crvo/2537558 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/. About CervoMedCervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB. Investor Contact: PJ KelleherLifeSci AdvisorsInvestors@cervomed.com617-430-7579","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}